Core Viewpoint - Four Seasons Pharmaceutical (00460) has signed a collaboration agreement with the U.S. biotechnology company AbaloneBio to jointly advance the development of innovative obesity treatment drugs, targeting metabolic-related G protein-coupled receptors (GPCRs) to enhance energy expenditure safely and effectively while maintaining or increasing muscle mass [1][1][1] Company Summary - Four Seasons Pharmaceutical's stock rose over 4%, currently trading at 1.51 HKD with a transaction volume of 46.35 million HKD [1][1][1] - The collaboration marks an extension of the partnership from a capital investment made earlier this year to a business execution level, reinforcing the company's innovative positioning in the weight loss sector [1][1][1] - The partnership aims to address the limitations of current weight loss therapies and meet the unmet clinical needs in the global obesity treatment market [1][1][1] Industry Summary - The collaboration is a significant step in optimizing and upgrading treatment solutions in the obesity treatment field, leveraging Abalone's technological advantages to accelerate the development of next-generation weight loss and muscle gain therapies [1][1][1] - This initiative is also an important move for the company to deepen its layout in the GPCR target area, which is crucial for future growth in the obesity treatment market [1][1][1]
港股异动 | 四环医药(00460)涨超4% 与美国AbaloneBio签署合作协议 深化GPCR靶点领域布局